Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy, Part I: Introduction and Indications

Area of Science:

• Oncology
• Surgical Oncology
• Medical Oncology

Background:

• Peritoneal carcinomatosis, often secondary to gastrointestinal and ovarian cancers, presents a significant treatment challenge.
• Cytoreductive surgery (CRS) involves the resection of cancerous tumors within the peritoneal cavity.
• Hyperthermic intraperitoneal chemotherapy (HIPEC) delivers heated chemotherapy directly to the peritoneum.

Purpose of the Study:

• To describe the combined approach of CRS with HIPEC for treating peritoneal carcinomatosis.
• To explain the mechanism of HIPEC in targeting residual micrometastatic disease.
• To highlight the potential survival benefits of this combined modality.

Main Methods:

• CRS involves surgical removal of visible cancerous tumors from the peritoneum.
• HIPEC entails circulating a heated chemotherapy solution (42° C) within the abdominal cavity for approximately 90 minutes via catheters.
• The heated chemoperfusate aims to eliminate residual cancer cells while sparing normal tissues.

Main Results:

• HIPEC targets residual micrometastatic disease after tumor debulking by CRS.
• The hyperthermia component of HIPEC is designed to selectively kill cancer cells.
• While typically not curative, the combined CRS with HIPEC can prolong patient survival.

Conclusions:

• The combination of CRS and HIPEC offers a targeted regional chemotherapy approach for peritoneal carcinomatosis.
• This treatment strategy aims to improve outcomes for patients with specific advanced cancers.
• Further discussion on CRS with HIPEC will follow in a subsequent article.